PPARγ activation inhibits growth and survival of human endometriotic cells by suppressing estrogen biosynthesis and PGE2 signaling

Endocrinology

Volumn 154, Issue 12, 2013, Pages 4803-4813

  Lebovic, Dan I ^a   Kavoussi, Shahryar K ^b   Lee, JeHoon ^c   Banu, Sakhila K ^c   Arosh, Joe A ^c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Austin Fertility and Reproductive Medicine Westlake IVF   (United States)

^c TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIGLITAZONE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; AROMATASE; PROSTAGLANDIN RECEPTOR;

APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; CELL GROWTH; CELL SURVIVAL; COMPETITIVE INHIBITION; CONTROLLED STUDY; ENDOMETRIOSIS; ENDOMETRIUM CELL; EPITHELIUM CELL; ESTROGEN SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL; ANTAGONISTS AND INHIBITORS; CELL LINE; CYTOLOGY; DRUG EFFECTS; ENDOMETRIUM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY;

AROMATASE; CELL LINE; DINOPROSTONE; ENDOMETRIUM; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; HYPOGLYCEMIC AGENTS; PPAR GAMMA; RECEPTORS, PROSTAGLANDIN; THIAZOLIDINEDIONES;

EID: 84888211643     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1168     Document Type: Article

References (55)

1. Kahn CR, Chen L, Cohen SE. Unraveling the mechanism of action of thiazolidinediones. J Clin Invest. 2000;106:1305-1307.
2. Savage DB. PPAR γ as a metabolic regulator: insights from genomics and pharmacology. Expert Rev Mol Med. 2005;7:1-16.
3. Semple RK, Chatterjee VK, O'Rahilly S. PPAR γ and human metabolic disease. J Clin Invest. 2006;116:581-589.
4. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARγ. Annu Rev Biochem. 2008;77:289-312.
5. Wanichkul T, Han S, Huang RP, Sidell N. Cytokine regulation by peroxisome proliferator-activated receptor γ in human endometrial cells. Fertil Steril. 2003;79(suppl 1):763-769.
6. Pritts EA, Zhao D, Ricke E, Waite L, Taylor RN. PPAR-γ decreases endometrial stromal cell transcription and translation of RANTES in vitro. J Clin Endocrinol Metab. 2002;87:1841-1844.
7. Galli A, Mello T, Ceni E, Surrenti E, Surrenti C. The potential of antidiabetic thiazolidinediones for anticancer therapy. Expert Opin Investig Drugs. 2006;15:1039-1049.
8. Rocha AL, Reis FM, Petraglia F. New trends for the medical treatment of endometriosis. Expert Opin Investig Drugs. 2012;21:905-919.
9. Hornung D, Chao VA, Vigne JL, Wallwiener D, Taylor RN. Thiazolidinedione inhibition of peritoneal inflammation. Gynecol Obstet Invest. 2003;55:20-24.
10. Giaginis C, Margeli A, Theocharis S. Peroxisome proliferator-activated receptor-γ ligands as investigational modulators of angiogenesis. Expert Opin Investig Drugs. 2007;16:1561-1572.
11. Bulun SE. Endometriosis. N Engl J Med. 2009;360:268-279.
12. Giudice LC, Kao LC. Endometriosis. Lancet. 2004;364:1789-1799.
13. Falcone T, Lebovic DI. Clinical management of endometriosis. Obstet Gynecol. 2011;118:691-705.
14. Guo SW, Olive DL. Two unsuccessful clinical trials on endometriosis and a few lessons learned. Gynecol Obstet Invest. 2007;64:24-35.
15. Kyama CM, Mihalyi A, Simsa P, et al. Non-steroidal targets in the diagnosis and treatment of endometriosis. Curr Med Chem. 2008;15:1006-1017.
16. Olivares C, Ricci A, Bilotas M, Barañao RI, Meresman G. The inhibitory effect of celecoxib and rosiglitazone on experimental endometriosis. Fertil Steril. 2011;96:428-433.
17. Aytan H, Caliskan AC, Demirturk F, Aytan P, Koseoglu DR. Peroxisome proliferator-activated receptor-γ agonist rosiglitazone reduces the size of experimental endometriosis in the rat model. Aust N Z J Obstet Gynaecol. 2007;47:321-325.
18. Demirturk F, Aytan H, Caliskan AC, Aytan P, Koseoglu DR. Effect of peroxisome proliferator-activated receptor-γ agonist rosiglitazone on the induction of endometriosis in an experimental rat model. J Soc Gynecol Investig. 2006;13:58-62.
19. Lebovic DI, Kir M, Casey CL. Peroxisome proliferator-activated receptor-γ induces regression of endometrial explants in a rat model of endometriosis. Fertil Steril. 2004;82(suppl 3):1008-1013.
20. Herington JL, Crispens MA, Carvalho-Macedo AC, et al. Development and prevention of postsurgical adhesions in a chimeric mouse model of experimental endometriosis. Fertil Steril. 2011;95:1295-1301.e1.
21. Lebovic DI, Mwenda JM, Chai DC, et al. PPAR-γ receptor ligand induces regression of endometrial explants in baboons: a prospective, randomized, placebo- and drug-controlled study. Fertil Steril. 2007;88:1108-1119.
22. Lebovic DI, Mwenda JM, Chai DC, Santi A, Xu X, D'Hooghe T. Peroxisome proliferator-activated receptor-(γ) receptor ligand partially prevents the development of endometrial explants in baboons: a prospective, randomized, placebo-controlled study. Endocrinology. 2010;151:1846-1852.
23. Peeters LL, Vigne JL, Tee MK, Zhao D, Waite LL, Taylor RN. PPAR γ represses VEGF expression in human endometrial cells: implications for uterine angiogenesis. Angiogenesis. 2005;8:373-379.
24. Sharma I, Dhawan V, Saha SC, Dhaliwal LK. In vitro effects of peroxisome proliferator-activated receptor-γ ligands on gene expression in lipopolysaccharide-induced endometrial and endometriotic stromal cells. Fertil Steril. 2011;95:829-831.e1-e5.
25. Streuli I, de Ziegler D, Borghese B, Santulli P, Batteux F, Chapron C. New treatment strategies and emerging drugs in endometriosis. Expert Opin Emerg Drugs. 2012;17:83-104.
26. Moravek MB, Ward EA, Lebovic DI. Thiazolidinediones as therapy for endometriosis: a case series. Gynecol Obstet Invest. 2009;68:167-170.
27. Attar E, Tokunaga H, Imir G, et al. Prostaglandin E2 via steroidogenic factor-1 coordinately regulates transcription of steroidogenic genes necessary for estrogen synthesis in endometriosis. J Clin Endocrinol Metab. 2009;94:623-631.
28. Bulun SE, Fang Z, Imir G, et al. Aromatase and endometriosis. Semin Reprod Med. 2004;22:45-50.
29. Bulun SE, Yang S, Fang Z, Gurates B, Tamura M, Sebastian S. Estrogen production and metabolism in endometriosis. Ann NY Acad Sci. 2002;955:75-85; discussion 86-88, 396-406.
30. Subbaramaiah K, Hudis C, Chang SH, Hla T, Dannenberg AJ. EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange. J Biol Chem. 2008;283:3433-3444.
31. Subbaramaiah K, Howe LR, Zhou XK, et al. Pioglitazone, a PPARγ agonist, suppresses CYP19 transcription: evidence for involvement of 15-hydroxyprostaglandin dehydrogenase and BRCA1. Cancer Prev Res (Phila). 2012;5:1183-1194.
32. Rubin GL, Zhao Y, Kalus AM, Simpson ER. Peroxisome prolifera-tor- activated receptor γ ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res. 2000;60:1604-1608.
33. Mu YM, Yanase T, Nishi Y, et al. Insulin sensitizer, troglitazone, directly inhibits aromatase activity in human ovarian granulosa cells. Biochem Biophys Res Commun. 2000;271:710-713.
34. Fan W, Yanase T, Morinaga H, et al. Activation of peroxisome proliferator-activated receptor-γ and retinoid X receptor inhibits aromatase transcription via nuclear factor-κB. Endocrinology. 2005;146:85-92.
35. Banu SK, Lee J, Satterfield MC, Spencer TE, Bazer FW, Arosh JA. Molecular cloning and characterization of prostaglandin transporter in ovine endometrium: role of mitogen activated protein kinase pathways in release of prostaglandin F2 α. Enodcrinology. 2008;149:219-231.
36. Banu SK, Lee J, Speights VO Jr, Starzinski-Powitz A, Arosh JA. Selective inhibition of prostaglandin E2 receptors EP2 and EP4 induces apoptosis of human endometriotic cells through suppression of ERK1/2, AKT, NFκB and b-catenin pathways and activation of intrinsic apoptotic mechanisms. Mol Endocrinol. 2009;23:1291-1305.
37. Lee J, Banu SK, Rodriguez R, Starzinski-Powitz A, Arosh JA. Selective blockade of prostaglandin E2 receptors EP2 and EP4 signaling inhibits proliferation of human endometriotic epithelial cells and stromal cells through distinct cell cycle arrest. Fertil Steril. 2010;93:2498-2506.
38. Wu MH, Lu CW, Chuang PC, Tsai SJ. Prostaglandin E2: the master of endometriosis? Exp Biol Med (Maywood). 2010;235:668-677.
39. Zeitvogel A, Baumann R, Starzinski-Powitz A. Identification of an invasive, N-cadherin-expressing epithelial cell type in endometriosis using a new cell culture model. Am J Pathol. 2001;159:1839-1852.
40. Wu Y, Starzinski-Powitz A, Guo SW. Trichostatin A, a histone deacetylase inhibitor, attenuates invasiveness and reactivates E-cadherin expression in immortalized endometriotic cells. Reprod Sci. 2007;14:374-382.
41. Lee J, Banu SK, Subbarao T, Starzinski-Powitz A, Arosh JA. Selective inhibition of prostaglandin E2 receptors EP2 and EP4 inhibits invasion of human immortalized endometriotic epithelial and stromal cells through suppression of metalloproteinases. Mol Cell Endocrinol. 2011;332:306-313.
42. Banu SK, Starzinski-Powitz A, Speights VO, Burghardt RC, Arosh JA. Induction of peritoneal endometriosis in nude mice with use of human immortalized endometriosis epithelial and stromal cells: a potential experimental tool to study molecular pathogenesis of endometriosis in humans. Fertil Steril. 2009;91:2199-2209.
43. Banu SK, Lee J, Speights VO Jr, Starzinski-Powitz A, Arosh JA. Cyclooxygenase-2 regulates survival, migration, and invasion of human endometriotic cells through multiple mechanisms. Endocrinology. 2008;149:1180-1189.
44. Banu SK, Lee J, Starzinski-Powitz A, Arosh JA. Gene expression profiles and functional characterization of human immortalized endometriotic epithelial and stromal cells. Fertil Steril. 2008;90:972-987.
45. Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev. 1994;46:205-229.
46. Woodward DF, Pepperl DJ, Burkey TH, Regan JW. 6-Isopropoxy-9-oxoxanthene- 2-carboxylic acid(AH6809), a human EP2 receptor antagonist. Biochem Pharmacol. 1995;50:1731-1733.
47. Crider JY, Griffin BW, Sharif NA. Endogenous EP4 prostaglandin receptors coupled positively to adenylyl cyclase in Chinese hamster ovary cells: pharmacological characterization. Prostaglandins Leukot Essent Fatty Acids. 2000;62:21-26.
48. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding. Anal Biochem. 1976;72:248-254.
49. Asselin E, Lacroix D, Fortier MA. IFN-tau increases PGE2 production and COX-2gene expression in the bovine endometrium in vitro. Mol Cell Endocrinol. 1997;132:117-126.
50. Johnson DG, Walker CL. Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol. 1999;39:295-312.
51. Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci. 2005;30:630-641.
52. Sánchez I, Dynlacht BD. New insights into cyclins, CDKs, and cell cycle control. Semin Cell Dev Biol. 2005;16:311-321.
53. Schwartz GK, Shah MA. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol. 2005;23:9408-9421.
54. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007;26:1324-1337.
55. Jiang X, Wang X. Cytochrome C-mediated apoptosis. Annu Rev Biochem. 2004;73:87-106.